Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.52 USD | +0.21% | +0.62% | -28.86% |
Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.86% | 1.46B | |
-19.96% | 10.67B | |
+44.22% | 3.22B | |
-35.49% | 2.09B | |
-17.21% | 2.04B | |
+18.85% | 1B | |
-4.37% | 734M | |
-36.92% | 391M | |
-45.92% | 379M | |
+13.32% | 343M |
- Stock Market
- Equities
- VCYT Stock
- News Veracyte, Inc.
- Veracyte : Partners With Bayer for Thyroid Cancer Program; Shares Climb